BD Diagnostics, a segment of Becton, Dickinson and Co., has announced it received FDA clearance to market a new MRSA test, according to a news release.
BD received clearance for the BD MAX MRSA molecular test. The assay is performed on the BD MAX system and is designed to identify patients colonized with MRSA, according to the company.
"The BD MAX MRSA assay is an easy-to-use, cost-effective method to identify patients colonized with this deadly superbug, which may support better outcomes for the patient and a safer hospital environment," said Tom Polen, president, BD Diagnostics - Diagnostic Systems, in the release. "FDA clearance of the BD MAX MRSA test gives our customers a new level of automation to optimize MRSA surveillance testing."
Becton, Dickinson and Co. is headquartered in Franklin Lakes, N.J.
Related Articles on FDA Clearances:
r4 Vascular Receives FDA Clearance for PTA Balloon
Intrinsic Medical Imaging Receives FDA Clearance for 3D Imaging Workstation
Teleflex Receives FDA Clearance for Peripherally Inserted Central Catheter